Haemonetics ( HAE - Free Report ) is well-poised for growth in the coming quarters, backed by the impressive business performance of the Hospital and Plasma segments. The company recently received FDA clearance for advancements to its NexSys PCS plasma collection system. The performance of the Hemostasis Management segment in its largest market, North America, is highly promising. However, its balance sheet is burdened with huge debt. Haemonetics' operations are also subject to intense competition from its peers.